Ignite Creation Date:
2024-05-05 @ 12:10 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00268151
Status:
TERMINATED
Last Update Posted:
2018-03-05
First Post:
2005-12-20
Brief Title:
Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer
Sponsor:
University of Louisville
Organization:
University of Louisville
Study Overview
Official Title:
Phase I Study of Oxaliplatin Eloxatin and Capecitabine Xeloda and Concurrent Radiation Therapy XELOX-RT in Non-Small Cell Lung Cancer
Status:
TERMINATED
Status Verified Date:
2018-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study was terminated due to lack of funding
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the most suitable dose of Oxaliplatin that can be safely given in combination with a low fixed dose of Capecitabine and a limited volume of radiation in patients with non-small cell lung cancer
Detailed Description:
The purpose of this study is to determine the maximum tolerated dose MTD and the dose limiting toxicity DLT of Oxaliplatin in combination with Capecitabine and radiation in subjects with non-small cell lung cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| OX-03-156 | None | None | None |